Sonelokimab (SLK) is a nanobody that inhibits IL-17 A&F. Phase 2 ARGO trial 207 active PsA pts Rx w/ SLK 120-mg or 60-mg q4wks or PBO or adalimumab. ACR50 at wk 12 was 60-mg WI=46%; 120-mg WI=46%; PBO 20%. PASI90: 60mg 77% vs 120mg 59% vs PBO 15% https://t.co/ra0NqvUEru https://t.co/FXT6kkXUzH

Tramadol not effective at chronic pain The strong opioid painkiller, tramadol, is not that effective at easing chronic pain for which it’s widely prescribed, finds a pooled data analysis of the available research, published online in BMJ Evidence Based Medicine. https://t.co/ORuA5Ip4pd

Osteoporosis Screening in High-Risk Men A VA Health Systems study of older male veterans found benefits of a remote model of screening that significantly improved osteoporosis screening, treatment, and adherence compared with usual care, with high patient and clinician https://t.co/Kt3mJLahdq

💬A JAKi CHAT: Shared Decision-Making in RA Dr. Curtis and Dr. Winthrop discuss approaches to patient conversations on risk with uncontrolled RA and treatment considerations, including JAKi safety. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/SZSiUOfo5V https://t.co/L8vovOOlHg

Retrospective study of 42 adult Still' pts Rx after 2010 w/ IL‐1 inhib if given < 6 mos (early) or > 6mos of Sxs. Early IL-1i had more inactive dz (CID)(67% vs 38%; P = 0.17) & steroid d/c w/in 6 mos. 10 major flares observed (62% after IL‐1i suspension or spacing) https://t.co/uD1meQuYvj

Review of GLP-1 agonist use in rheumatology - with benefits beyond DM, obesity, improved survival, reduced major cardiovascular and renal events. Anti-inflammatory & chondroprotective effx shown benefit in knee OA & pain. GLP-1RAs do not prevent gout attacks. More research https://t.co/1HDgfc7YwT

Not all difficult-to-treat RA will have rapid radiographic progression A study of radiographic outcomes in difficult-to-treat rheumatoid arthritis (D2T RA) and poly-refractory RA (pr-RA) show a subset in whom damage is rapid and in need of more aggressive therapy. https://t.co/WrwyeW5qsj

Multimorbidity in SLE: metanalysis of 3 studies (1175 pts) saw Multimorbidity (by higher Charlson comorbidity index/CCI), is a strong independent predictor of mortality in SLE (OR 3.92). In SLE, the most freq comorbidities were DM, CVD, COPD, renal/lung/CNS Dz https://t.co/auIb3vkLkN

Optimizing DMARD Therapy in Rheumatoid Arthritis A phase IV trial from Spain demonstrates that optimization of therapy by lessening biological DMARDs in rheumatoid arthritis (RA) may be feasible, with a low risk of flare. https://t.co/37O3mAulGy https://t.co/y7OkkzRZUg

FDA has approved nerandomilast (PDE4b inhibitor) for treatment of adults with idiopathic pulmonary fibrosis (IPF). Approval is based on 2 RCTs, FIBRONEER-IPF & FIBRONEER-ILD, that show slowing of lung function decline IP & progressive pulmonary fibrosis (PPF) pts. https://t.co/uza0JTZDMP

RheumNow is LIVE from #ACR25 Oct 24–29. KOL perspective videos, clinical-trial highlights, daily recaps & live streaming—all in one feed. https://t.co/pPwJNOyEFU